Cedars-Sinai Medical Center

medical staff pulse newsletter

Text size: A A A Print this issue
A BI-WEEKLY PUBLICATION FROM THE CEDARS-SINAI CHIEF OF STAFF January 12, 2018 | Archived Issues

Meetings and Events


Grand Rounds


Upcoming CME Conferences


Milestones

Do you know of a significant event in the life of a medical staff member? Please let us know, and we'll post these milestones in Medical Staff Pulse. Also, feel free to submit comments on milestones, and we'll post the comments in the next issue.

Submit your milestones and comments.

Share Your News

Won any awards or had an article accepted for publication? Share your news about professional achievements and other items of interest.

Click here to share your news

FDA Issues New Safety Measures for Gadolinium-Based Contrast Agents

The U.S. Food and Drug Administration (FDA) is requiring a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) because of concerns about gadolinium remaining in patients' bodies, including the brain, for months to years. Gadolinium retention has not been directly linked to adverse health effects in patients with normal kidney function, and the FDA has concluded that the benefit of all approved GBCAs continues to outweigh any potential risks.

The FDA website has more information.

FDA: Agency Removes Warning About Asthma-related Death

The FDA is removing its most prominent warning about asthma-related death from the drug labels of medicines that contain both an inhaled corticosteroids (ICS) and long-acting beta agonists. A review of four large clinical-safety trials showed that treating asthma with long-acting beta agonists in combination with inhaled corticosteroids does not result in significantly more serious asthma-related side effects than treatment with ICS alone.

The FDA website has more information.